Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 5.5% – Time to Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) fell 5.5% during trading on Monday . The company traded as low as $27.70 and last traded at $27.70. 3,055 shares changed hands during trading, a decline of 89% from the average session volume of 28,352 shares. The stock had previously closed at $29.31.

Analyst Ratings Changes

A number of research firms have weighed in on AAPG. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Oppenheimer assumed coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. BTIG Research assumed coverage on Ascentage Pharma Group International in a research note on Monday, November 10th. They set a “buy” rating and a $50.00 target price for the company. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a report on Monday, November 24th. Finally, Piper Sandler started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $48.50.

Ascentage Pharma Group International Trading Up 5.2%

The business’s 50 day simple moving average is $31.96 and its 200 day simple moving average is $36.75. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds have recently added to or reduced their stakes in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International during the third quarter worth about $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000. Chevy Chase Trust Holdings LLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $227,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.